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We studied the molecular binding specificity of two rabbit polyclonal sera gcneratcd against phcnolic glycolipid antigens namely PheGl B and 
PheGl B-3 from Mycobacteriutn bovis BCG. PheGl B is the well-known mycoside B (2.O-Me-+L-Rhap l--taglycone), while PheGl B-3 is a recently 
found glycolipid (cr+Rhap-( I -P3)-2.0.Mc-o+Rhap l+ aglycone). The interaction specificity was mainly explained in terms of the cavity volume 
of the antibodies paratopc. The anti-PheGl B antibodies patatope fits the 2-O-Me-cl+Rhap ligand, while that of anti-PIleG B-3 binds the 
disaccharide moiety of PheGl B-3, and, with a higher affinity, the monosaccharidic unit localized at the non-reducing end. The B-3 antigen aflinity 
is higher than that of antigen B for their homologous antibodies. This can be explained by the fact thnt the antibodies against phenolic glycolipid 
B-3 bind optimally to two sequential glycosyl residues uggesting the presence of two subsites. The immunoglobulin subsite with the major affinity 
binds the monosaccharidic unit localized at the non-reducing end. 
Mycobucreriunl bovis BCG; Epitope; Phenolic glycolipid 
1. INTRODUCTION 
In the last decade it has been shown that most myo- 
cardial cell walls contain species-specific immunoreac- 
tive glycokpids [l-3]. These glycolipids are subdivided 
according to their structure into four groups; the phe- 
nolic glycolipids (PheGl), the trehalose-containing 
lipooligosaccharides (LOS), the C-mycoside glycopcpti- 
dolipids (GPL) and finally the serine-containing 
glycopeptidolipid [4]. 
Whatever the structure of these antigens their epitope 
was delineated in the sugar part. More precisely their 
species pecificity arises from the unique structure of the 
monosaccharide unit located at the non-reducing end of 
the oligosaccharide part. In some cases, the terminal 
monosaccharide structure was assigned to monosac- 
charides newly-found in nature, such as, 2,6-dideoxy-4. 
O-Me-arabino-a-o-hezopyranoside [5,6], 4,6-dideoxy-2- 
O- Me-3-C-Me-4-(2’-methoxypropionamido)-cr- L-vnan- 
no-hexopyranoside [7,8], and 4-lactylamido-3-O-Me- 
4,6-didcoxy-p-Glcp [9] which comprised the M. kansasii 
phenolic glycolipid, the M. kansusii LOS and A4. uvium 
complex serovar 12 GPL, respectively. In other cases, 
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the distal monosaccharide structure arises from ubiqui- 
tous monosaccharides such as a+Rhap, M-L-Fucp, ,5-p- 
Glcp, and &D-Manp but bearing either methoxyl or 
acetoxyl groups [lO-141. 
From a structural point of view, the process of carbo- 
hydrate epitope binding by antibodies is a key factor in 
the understanding of the mechanisms involved in the 
specific recognition of a carbohydrate ligand by immu- 
noglobulins [15], Recently Nashed et al. [16] showed 
that IgA monoclonal anti-isomaltose antibody binds 
optimally to four sequential glucopyranosyl residues 
and that the protein subsite possessing the major affin- 
ity binds to the terminal non-reducing lucosyl unit, 
Our laboratory is involved in the purification and 
structural elucidation of mycobacterial immunoreactive 
glycolipids. We have recently described the presence, in 
the cell walls of Mycobacferium his BCG, besides the 
well known mycoside B (2-O-Me-a-t-Rhap l-+diacyl- 
phenolphthiocerol), of two newly found phenolic gly- 
colipids, namely PheGl B-2 and PheGl B-3. Their car- 
bohydrate structures were assigned respectively, to &L- 
Rhap and a-t-Rhap-( l-+3)-2-O-Me-or-L-Rhap [ 171. In 
the present work the ligand binding specificity of rabbit 
polyclonal anti-PheGl B and anti-PheGl B-3 sera are 
determined. The experimental approach was based on 
affinity measurements by ELISA of structurally related 
phenolic glycolipids from other mycobacterial species 
and synthetic methyl glycosides, The process of carbo- 
hydrate pitope binding as well as the recognition mech- 
anisms will be discussed according to the immunoglob- 
ulin cavity size and hydrogen bonding interactions. 
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2. MATERIALS AND METHODS 
The purification and characterization of glycolipids from M. boeis 
BCG and hf. kansusii have been described in previous work [6,17]. 
Purification of PheGl M from M, marinum was performed as de- 
scribed by Fournit! et al. 161. 
2.2. Monosacdarides 
Methyl glycosides were purchased from Sigma except methyl-a- and 
/J-L-rhamnopyranoside, which were obtained after treatment of a-~- 
rhamnopyranosc by anhydrous methanol/2 M HCI. for 2 h at 80°C 
and purification by HPLC as previously described [l%]. Methyl&xi 
methyl a+rhamnopyranosides were synthesized and purified by 
HPLC as previously described [IS]. 
2.3. Antiserum prepararioll 
Two 2-month-old ‘fauvc de Bourgogne’ rabbits were inoculated 
intradermally with 3 mg of phenolic glycolipid B or B-3 in incomplete 
Freund’s adjuvan::PBS (pH 7.2) emulsion followed by one or two 
booster injections (2 mg) on days 20 and 45 after the first immuniza- 
tion. Antibody titers were determined from test bleed using an ELlSA 
prooedure, 
2.4. Comperirion ms~ in ELlSA 
ELISA was carried out as previously described [17] with some 
modifications. Briefly, 50 ~1 of PheG1 B or PheGl B-3 dissolved in 
absolute ethanol/hexane (1:I) at a concentration of 25 and S PlJml, 
respectively, were coated by evaporation at 37°C overnight onto wells 
of microtitrc plates (Nunc-Immune Plate I). The ELISA competition 
test was done by incubating antisera t the indicated ilutions in wells 
of microtitre plates with potential inhibitor. The inhibitory glycolipids 
were thoroughly suspended at various concentrations in PBS + so- 
dium deoxycholatc (1 m@ml) + 0.4% powdered efattcd milk, Inhib- 
itory sugar solutions were made in PBS + 0.4% powdered efatted 
milk. 90 ,ul of a serial dilution of test antigen or test methyl glycoside 
and 10 ,uI of a 10/X dilution of antiserum were added to each well (X 
= 100 for the PheGl B antiserum and 50 for PheGl B-3 antiserum) 
for 2 h at 37OC. After washings, anti-rabbit Ig horseradish peroxidac 
conjugate (Amersham France, Lcs Ulis, France) diluted 1 in 1,000 in 
PBS + 1% BSA was added followed by a 2 h incubation at 37°C. After 
washing three times, 100/l of a solution of 2,2’ azinobis (3.ethylbcnz- 
thiazolinc sulfonic acid) at aconcentration of 1 mg/ml and 0.01% H,O, 
in acetate buffer were added to each well. Absorbance was read at 405 
nm with a Multiskan apparatus (Flow Laboratories Inc,, McLean, 
VA, USA). 
The remaining activity percentage was calculated as follows: 
where B = absorbance with inhibitor and coared antigen, C = with 
inhibitorand without coated antigen, D = without inhibitorsand with 
coated antigen and E = without inhibitor and without coated antigen. 
2.5. Mohdar mode&ng 
The representations of the carbohydrate parts of the phcnolic gly- 
colipids (Figs. 2 and 4) were drawn using the Alchemy program (Tri- 
pos Associates). The site cavity sizes of the anti-PheGl B and anti- 
PhcGl E-3 antibodies were modelizecl from the CPK models of their 
respective antigen. 
3. RESULTS AND DISCUSSION 
3.1. AntbPheGl B antibodies molecular specijicify 
In order to determine the molecular specificity of the 
anti-Phe-Gl B antibodies, their binding to other myco- 
bacterial phenolic glycolipids was investigated. The 
phenolic glycolipid from M. kattsasii (PheGi K-I), the 
Fig. I, Inhibiticn ELISA of PheGl B antiserum binding to coated 
PheGl B by (A) phcnolic glycolipids B. B-l, B-2 and B-3 from M. bovis 
BCG, PheCil M from M. mrinum and PheGi K-I from M. kunsdi 
or by (B) methyl glycosidcx methyl a-L-Rhap, methyl ?-0Mru-L- 
Rhap, methyl 3-O-Me-o-L-Rap/t. methyl 4-O-MC-a+Rhap, methyl 
a-D-Glcp, methyl cc-D-Many and methyl a-o&alp. Following coating 
of PhcGl B, anti-PheG 1 B serum diluted 1 in 100 (final dilution) was 
incubated with varying concentrations of inhibiting glycolipids or 
methyl glycosides for 90 min. The amount of antibodies bound was 
determined. Each point represents he arithmetic mean for threedeter- 
minations. 
phenolic glycolipids B-l, B-2 and B-3 from M. bovis 
BCG and the phenolic glycolipid from h& wrinum 
(PheGl M) were selected (their complete structures are 
summarized in Table I). 
Binding studies by competition ELISA (Fig. 1A) re- 
veal that PheGl B-l binds to antibody with the same 
affinity as PheGl l3 suggesting that the methoxyl group 
of the aglycone part is not involved in the binding proc- 
ess. Moreover, the complete loss of PheGl K-I binding 
clearly demonstrates the absence of involvement of the 
aliphatic chain and consequently the delineation of the 
PheGl B epitope to the 2-O-Me-a+Rhap. These results 
extend the previous d ata showing that M. ieprae and M. 
kansasii phenolic glycolipidic epitopes are delineated to 
the carbohydrate part and more precisely to the disac- 
charidic unit located at the non-reducing end [19-211. 
23 
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Fig. 2. Schematic representation of the binding site of the anti-PheGl B antibody with the following ligands: 
(a) 2.O-Me-a+Rhap I + 0 phenyl 
(b) 3&Me-a-L&hap I+ 0 phcnyl 
(c) 4-O-Me-a+Rhap I -_) 0 phenyl 
(d) a-L-Rhap I+ 0 phenyl 
The PheGl B-2 ligand significantly binds the anti- 
PheGl B antibodies through its a-L-Rhap, while a com- 
plete loss of binding appears for the PheGl M ligand. 
PheGl B=3 shows a lower affinity than PheGl B-2 al- 
though they share the same monosaccharide, a-L-Rhap, 
at the nonsreducing end. 
To determine the specificity of 2-O-Me-a-t-Rhap 
binding, methyl glycosides of Rhap with methoxyl 
groups at C-3 or C-4 were selected together with methyl 
Pc-L-Rhap. As expected, the binding studies show that 
methyl 2-O-Me-c+t-Rhap optimally binds the anti- 
PheGl B antibodies in agreement with the fact that this 
glycoside residue is the PheG 1 B epitope (Fig. 1 B). Nev- 
ertheless, it can be observed that the methyl 2-0-a-L- 
Rhap affinity is 500-times lower than that of Phe Gl B. 
Similar results have been reported by Fujiwara et al. 
[Zl] concerning the binding of the phenolic glycolipid 
from M. leprae and their related monosaccharide and 
dissacharide pitopes to lepromatous leprosy sera. Un- 
like methyl glycoside pitopes glycolipid antigens have 
an amphipatic structure which allows micelle formation 
in aqueous olution. The difference in antibody affinity 
Table I 
Structures of the phenolic glycolipids 
Phenolic glycolipids from 
M. bovis BCG 
PheGl B 
PheGl B-l 
PheGl B-2 
PheGl B-3 
Carbohydrate structure 
2-O-Me-Q+Rhap 
I-O-Me-a+Rhap 
a+Rhap 
a-r-Rhap (143) 
2-O-Me-a+Rhap 
Phenolgiycol structure 
Phenolphthiocerol 
Phenolphthiodolone 
Phenolphthiodolone 
(major homolog) 
Phenolphthiocerol 
Patty acid structure 
Mycocerostc Czb, Ca,, CW, C,O. 
Mycooerosic C,,,, CLllr CzA, C1,. 
Mycocerosic CzB, Cz,, C2+ 
Mycocerosic Ca, Cz7, Cz4, 
M. konsusii 
PheGl K-l 2,6-dideoxy40-Mc-a-p-arabino- 
hexp-(143).~-O-AC-~-O-MC- 
a-L-Fucp-(I +3)-2-0.Me-a-L-Rhw 
(I->3)-2,4-di-O-Me-a+Rhnp 
Phenolphthioccrol Myoocerosic Clu, C,,,, CJ1, 
bf* mm-hum 
PheGl M 
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Fig. 4. Schematic representation f the biding site of the anti-Phffil 
B-3 antibody with or-r_-Rhap (I-13)-2.O-Mes-t&hap 140 phenyl. 
Fig. 3. Inhibition ELlSA of PheGi B-3 anliscrum binding to coated 
PheGl B-3 by (A) phenolic glycolipids B, B-1, B-2 and B-3 from M. 
bovis BCG or by (B) methyl glycosides: methyl a-t.-Rhap, methyl 
j-L-Rhap and methyl 2-0-Me-a-r.-Rhap, Conditions are the same as 
in Fig. 1 except hat anti-PheGl B-3 serum was diluted 1 in 50 (final 
diitition). 
for these two types of molecules is likely to arise from 
better accessibility of carbohydrate parts of glycolipids 
at the micelle surface. Thus in order to discuss these 
respective binding specificities, one can only anaiyse the 
relative affinity values of the methyl glycoside ligands 
on one side or those of glycolipids on the other. Methyl 
cc-L-Rhap also binds the anti-PheGl B antibody but 
with a lower affinity than methyl 2.O-Me-a+Rhap. 
The complete loss of binding for the methyl 3-Q-Me-a- 
L-Rhap are more striking and are in agreement with the 
unbinding of the PheGl M, and the methyl 4-O-Me-a- 
L-Rhp. From these results ir emerges that ligand un- 
binding is restricted to t.he location of the methoxyl 
group on the a+Rhap unit. 
Considering the apolar nature of the phenolic glyco- 
lipids it can be assumed that hydrophobic in?eractions 
play a key role in promoting the stereospecific binding. 
It can be suggested that this process occurs through the 
presence of a cavity in the anti-PheGl B immunoglob- 
ulin whose size can be estimated from the Van der 
Waals radius of the PheGl B epitope: 2-O-Me-cr-t- 
Rhap. Thus, the binding of the unmethoxylated Rhap 
can bc explained, as illustrated in Fig. 2, by the decrease 
of the steric hindrance due to the substitution of a C-2 
methoxyl group (PheGl B) by a hydroxyl group (PheGl 
B-2). Moreover, the lower affinity of PheGl B-3 com- 
pared to PheGl B-2 indicates that the penultimate mo- 
nosaccharide of PheG 1 B-3 is the cause of this effect by 
increasing the steric hindrance of the terminal monosac- 
charide unit. As shown in Fig. 2 steric hindrance ap 
pears to be the major factor of the unbinding of methyl 
3-O-Me-a+Rhap. From these data, it can be specu- 
lated that a methyl glycoside ligand having a volume 
smaller than that of methyl 2-O-Me-a+Rhap must be 
able to bind the anti-PheGl B antibodies with a lower 
affinity. This is the case of methyl a-L-Rhap, but also 
of methyl a-D-Manp, a-D-GlCp and a-D-Galp (see Fig. 
1B). 
It has been shown that hydrogen bonds also play a 
key role in carbohydrate antigen-antibody binding. 
Both the C-3 and C-4 hydroxyl groups of 2-O-Mea- 
L-Rhap can participate in hydrogen bonding by either 
H donation or H acceptance from the protein. Thus the 
spatial orientation of both C-3 and C-4 hydroxyl 
groups, resulting from the arrangement of the 2-O-Me- 
a-L-Rhap epitope in the immunoglobulin cavity site, 
plays a key role in the stereospecific binding. The posi- 
tion of the 2-O-Me-a-t_-Rhal, is mainly controlled by the 
Van der Waals interactions which are proportional to 
re6 (r, distance). The lower volume of a+Rhap, calcu- 
lated from the Van der Waals radius, compared to the 
cavity size of the anti-PheGl B antibody, led to a higher 
freedom, suggesting that both C-3 and C-4 hydroxyl 
groups are not optimally pointed to establish ydrogen 
bonds with the immunoglobulin amino acids. Such a 
process explains the lower affinity of a+Rhap binding 
compared to that of 2-O-Mea-L-Rhap. 
25 
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From these data two major parameters emerge for 
understanding the specific binding process of apolar 
glycolipids by antibodies: the Van der Waals volume of 
the immersed epitope ligand compared to the cavity size 
of the binding site, and the stereospecific linkage by 
hydrogen bonding. Thus it can be speculated that car- 
bohydrate pitopes of lipopolysaccharides [22] and phe- 
nolic glycolipids [6] containing dideoxyhexoses attheir 
non-reducing end will genemte antibodies of higher mo- 
lecular specificity. 
3.2. Anti-PheGi B-3 antibody tnolecular spect@ity 
In a similar fashion, the binding process between 
PheGl B-3 and anti-PheGl B-3 antibodies was investi- 
gated (Fig. 3A). The optimally binding iigand is the 
PheGl B-3 (estimated affinity 1 PM), and as expected 
the PheGl B-3 epitope is delineated in the sugar part, 
cr-t-Rhap-(l-3)-2-O-Me-ar-L-Rhap. The anti-PheGl 
B-3 antibodies also bind with a lower affinity to PheGl 
B-2, whose carbohydrate structure is the a-L-Rhap unit 
but is unable to bind to PheGl B. 
Binding studies of the synthetic methyl glycosides 
(Fig. 3B) show that the a- and p-anomers of methyl 
L-Rhap optimally bind the anti-PheGl B-3 antibodies 
while methyl 2-O-Me-a+Rhap binding must be so 
weak that our method can barely quantitate it. From 
these data it emerges that the a-L-Rhap unit located at 
the non-reducing end of PheGl B-3 binds an immuno- 
globulin subsite with a higher affinity. However the 
substantial decrease of PheGl B-2 binding suggests that 
the penultimate monosaccharidic unit, 2-O-Me-a-t.- 
Rhap, is also involved in PheGl B-3 binding. From 
these data, and by analogy with the monoclonal anti- 
dextran binding site [16] it can be proposed that the 
anti-PheGl B-3 antibodies possesses two subsites, one 
with the major affinity and binding to the terminal mo- 
nosaccharide unit (subsite I) while the other (subsite II), 
binds to 2-O-Me-a-L-Rhap with a lower affinity which 
can not be quantitated by the technique used (Fig. 4). 
It can also be noticed that the affinity of the glycolipid 
B-3 for the anti-PheGl B-3 antibodies is approximately 
six-times higher than that of PheGl B for its antibodies. 
This can be explained by the fact that antibody binds 
optimally to two sequential glycosyl residues. 
Finally it is interesting to consider that mostly oli- 
goclonal antibodies are generated by the rabbit immune 
system when purified phenolic glycolipids such as 
PheGl B and PheGl B-3 were injected. Effectively, one 
could easily define a single epitope, delineated at 2-O- 
Me-a-L-Rha.0 unique sugar on the PheGl B antigen, by 
the occurence in the whole serum of immunoglobulins 
that only bind the sugar part. Therefore it is obvious to 
conclude that these glycolipid antigens have structural 
regions rendered cryptic (the aglycon chain), together 
with obligatory antigenic determinant (the oligosac- 
charide), to the immune system. 
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